Curatis "Next-generation mRNA vaccine 'TAP104' Phase 1 Clinical Trial Progressing Smoothly"

Non-clinical Trials Conducted for Additional Variants Including Omicron

Curatis Osong Bioplant.

[Asia Economy Reporter Lee Gwan-joo] Curatis announced on the 7th that the Phase 1 clinical trial of the next-generation mRNA COVID-19 vaccine 'TAP104' is progressing smoothly.

QTP104, which received approval for its Phase 1 clinical trial plan last July, is the first next-generation mRNA vaccine developed domestically. Compared to existing mRNA vaccines, it can induce a strong immune response with a smaller dose and is attracting attention for its high safety.

QTP104 is currently undergoing clinical trials at Sinchon Severance Hospital and Gangnam Severance Hospital. Starting with the first subject dosing last year, it received a safety evaluation through the DSMB (Data Safety Monitoring Board) based on adverse drug reactions and blood test results, and recently entered clinical trials with increased dosage. Recruitment of clinical trial subjects is also ongoing.

The Curatis Bio Research Institute has also conducted non-clinical experiments to evaluate the efficacy of QTP104, confirming that QTP104 strongly induces neutralizing antibodies capable of defending against both the original COVID-19 virus and the Delta variant. The defense effect against the Omicron variant (neutralizing antibodies, cellular and humoral immune formation) is currently in the experimental stage, and it is expected that the defense effect against Omicron will be confirmed soon. Additionally, based on the gene manipulation technology accumulated during the vaccine development process, continuous development of vaccines against various COVID-19 variants is underway.

Curatis is accelerating preparations for listing on KOSDAQ by applying for a technology evaluation for a special technology listing on December 30 last year, based on its vaccine development technology.

Choi Yoo-hwa, Executive Director and Head of Clinical at Curatis, said, "QTP104 is progressing smoothly through Phase 1 clinical trials in close cooperation with domestic health authorities such as the Pan-Government Support Committee, the Ministry of Health and Welfare, and the Ministry of Food and Drug Safety, and safety is being demonstrated through clinical data collection." She added, "To respond to ongoing concerns about variant viruses, non-clinical trials are being conducted on new variants such as Omicron to verify neutralizing antibodies and T-cell immunity." She continued, "We hope to contribute significantly to ending COVID-19 infections by focusing the company's capabilities to successfully carry out the clinical trials of QTP104."

This content was produced with the assistance of AI translation services.